Anticonvulsants as Anxiolytics, Part 1

Tiagabine and Other Anticonvulsants With Actions on GABA

Stephen M. Stahl, M.D., Ph.D.

**Issue:** Anticonvulsants that enhance GABA neurotransmission may also have potential as novel anxiolytics.

---

**GABA AND ANXIETY**

Anticonvulsants are proving to have much broader utility in psychiatry and neurology than in just the treatment of seizure disorders, with the expanded indications dependent on the specific pharmacologic mechanism of action of a given anticonvulsant. Increasing evidence shows dysfunction of the γ-aminobutyric acid (GABA)-ergic system to be pivotal to the pathogenesis of anxiety; thus, augmenting GABA neurotransmission may be expected to have anxiolytic actions.

**POTENTIAL ANXIOLYTIC ACTIONS OF ANTICONVULSANTS**

**Direct GABAergic Mechanisms**

An association between enhancement of GABA neurotransmission and anxiolytic actions is supported by the well-documented efficacy of benzodiazepines (also anticonvulsants) in anxiety disorders. Other anticonvulsants may enhance GABA neurotransmission via other mechanisms, including selective inhibition of GABA reuptake, inhibition of the enzyme GABA transaminase (GABA-T), and increased synthesis and release of GABA secondary to inhibition of voltage-gated ion channels. These actions are not only appealing as possible novel anxiolytics, but are also beginning to show anxiolytic efficacy in early trials.

Selective GABA reuptake inhibitors (SGRIs). The synaptic actions of GABA are terminated by high-affinity reuptake systems on presynaptic GABA neurons and neighboring glia and can be blocked by SGRIs such as tiagabine. These actions are analogous to those of SSRIs (selective serotonin reuptake inhibitors) on the high-affinity reuptake system of serotonin neurons.

Four distinct genes for GABA transporters have been cloned: GAT-1, GAT-2, GAT-3, and BGT-1. GAT-1 is the most abundant and may act not only to terminate GABA action by transporting GABA into presynaptic GABAergic terminals but also to influence excitatory and inhibitory transmission by modulating the spread of GABA from within the synaptic cleft to extrasynaptic receptors. The precise roles of GAT-2, GAT-3, and BGT-1 have yet to be elucidated. At present, the only SGR clinically available is tiagabine, an analog of the GABA reuptake inhibitor nipecotic acid. Of the GABA transporters, tiagabine is the most highly selective for GAT-1.

Small, open-label studies have shown that tiagabine monotherapy may improve anxiety symptoms and sleep quality in patients with generalized anxiety disorder and posttraumatic stress disorder (PTSD). Augmentation with tiagabine also improves anxiety symptoms in patients with treatment-refractory anxiety disorders and preliminary data are encouraging in patients with PTSD and comorbid disorders, anxiety and comorbid depression, and panic disorder with or without agoraphobia.

Selective GABA-T inhibitors. Vigabatrin is an anticonvulsant that robustly increases brain GABA levels by irreversibly inhibiting GABA-T, the enzyme responsible for the degradation of GABA. Preliminary results suggest that vigabatrin may have anxiolytic activity in humans, given that 7-day vigabatrin treatment produced a marked reduction in cholecystokinin-tetrapeptide–induced panic in healthy volunteers. Drug toxicity causing the development of visual field defects in some patients taking vigabatrin is expected to preclude availability of the drug in the United States, but develop-
Take-Home Points

- GABA is the major inhibitory neurotransmitter in the central nervous system and plays a key regulatory role in neuroanatomic circuits that hypothetically mediate fear in anxiety disorders.
- Numerous anticonvulsants may enhance GABA neurotransmission via several different mechanisms, including selective inhibition of GABA reuptake, inhibition of GABA transaminase, and increased synthesis and release of GABA secondary to inhibition of voltage-gated ion channels.
- Anticonvulsants with robust GABA-enhancing actions may eventually prove to be effective anxiolytics.

REFERENCES

17. Sills GJ. Pre-clinical studies with the GABAergic compounds vigabatrin and tiagabine. Epil Disord 2003;5:51–56